Safety assessment of immunomodulatory drugs based on group-specific polysaccharidesin their clinical application
The article deals with the safety profile of immunomodulatory drugs Frugluminum A and Frugluminum B using in the complex therapy of secondary immunodeficiency in patients with infectious diseases (nonspecific acute surgical infection of soft tissues, community-acquired pneumonia, pulmonary tuberculosis) and oncohematological diseases (chronic lymphatic leukemia). It was detected, that drug administering in patients did not cause statistically significant changes in the values of clinical blood analysis in comparison with parameters in the respective placebo groups excepting absolute leukocyte count and lymphocyte ratio. The normalization of these parameters is the result of immunomodulatory effects of the drugs; it shows their clinical effectiveness. Frugluminum A and Frugluminum B in intramuscular course administration do not have a toxic effect on the liver function and excretory function of kidneys. The drugs are well tolerated by patients and do not cause systemic and local adverse reactions.